Intraday data delayed at least 15 minutes or per exchange requirements. The analyst initiated coverage on … Cookie Notice. 2020. It has a market capitalization of US$18b. Analyst Ratings Network (ARN) provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target changes. X. Copyright © 2021 MarketWatch, Inc. All rights reserved. RS line at new highs. I n recent trading, shares of NovoCure Ltd (Symbol: NVCR) have crossed above the average analyst 12-month target price of $21.50, changing hands for $21.75/share. Earnings vs Savings Rate: ... Future Dividend Coverage: ... NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Date Research Firm Action Current PT; 9/23/20: Northland Capital Markets: Initiates Coverage … Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks, Stock-market bulls brace for major gut check as earnings, Fed and GDP loom, 3,000 arrested in Russia protests demanding Navalny’s release, Gamers threaten to defect to PlayStation after Xbox Live price hikes, 3 ways President Biden’s proposed stimulus checks will be different from Trump’s payments, NVCR will report 2020 earnings on 02/24/2022, NVCR will report Q4 2020 earnings on 04/29/2021. The analyst initiated coverage of Luminar stock with a Buy rating and $38 price target. They issued an “overweight” rating and a $85.00 price objective for the company. Toronto, Ontario ... as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10 -K filed on February 22, 2018, or in Normally institutions would own a significant portion of a company this size. Privacy Notice, and By using this site you agree to the Yahoo | December 4, 2020. Salaries posted anonymously by Novocure employees. Novocure earned a media sentiment score of 1.3 on InfoTrie's scale. Analyst Type Rating (Past) PT (Past) Start $ (End $) % Chg. NovoCure Limited (NVCR) will report its next earnings on 27-Apr-17. NovoCure also reported a profit of US$0.02, which was a nice improvement from the loss that analysts … Financial, in millions. In a report issued on January 5, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $18.00 price target. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. RS line at new highs. Découvrez comment nous utilisons vos informations dans notre Politique relative à la vie privée et notre Politique relative aux cookies. Earnings vs Savings Rate: ... Future Dividend Coverage: ... NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Northland Securities started coverage on shares of NovoCure in a report on Wednesday, September 23rd. ET by Tomi Kilgore Novocure stock price target raised to $105 from $48 at SunTrust RH Piper Sandler boosted their target price on shares of NovoCure from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, October 29th. Log in to see them here or sign up to get started. NovoCure is a pretty big company. Research news, charts, stock market performance and earnings. Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. Learn about NVCR (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a 14-day free … NovoCure (NASDAQ:NVCR) Q3 ... where we continue to have ongoing productive coverage discussions with the Federal Office of Public Health. Yahoo | December 4, 2020. The Durable Medical Equipment Medicare Administrative Contractors (DME MACs) have issued a proposed local coverage determination that provides coverage of Novocure’s Optune Tumor Treating Fields device for treating newly diagnosed glioblastoma at … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. 02, 2019, 8:00 a.m. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. This browser is no longer supported at MarketWatch. Finally, Piper Sandler initiated coverage on Novocure in a report on Sunday, April 19th. December 31. Fly Intel: Top five analyst downgrades. Good morning, guys. The company’s shares opened today at $21. 3 strong gains from the 50-day line. The Durable Medical Equipment Medicare Administrative Contractors (DME MACs) have issued a proposed local coverage determination that provides coverage of Novocure’s Optune Tumor Treating Fields device for treating newly diagnosed glioblastoma at certain cancer centers.

Pour autoriser Verizon Media et nos partenaires à traiter vos données personnelles, sélectionnez 'J'accepte' ou 'Gérer les paramètres' pour obtenir plus d’informations et pour gérer vos choix. It is extremely rewarding to work for a company that is so driven by our patient-forward vision. Quotes Snapshot > NVCR. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresse IP, Navigation et recherche lors de l’utilisation des sites Web et applications Verizon Media. ... Analyst. Fourth quarter and full year 2020 financial results to be reported Thursday, Feb. 25, 2021 Analyst Ratings Network (ARN) provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target changes. NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, October 29th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and six have given a buy recommendation to the company. Top Northland Securities analyst Jason Wittes has just initiated coverage of medical tech stock NovoCure with a buy rating and $200 price target. Novocure analyst and investor briefing IASLC 19th World Conference on Lung Cancer September 25, 2018 . Novocure will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. Wedbush analyst D. Nierengarten now anticipates that the medical equipment provider will earn $0.29 per share for the year, up from their prior estimate of $0.23. Intraday Data provided by FACTSET and subject to terms of use. Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019. Finally, Piper Sandler initiated coverage on Novocure in a report on Sunday, April 19th. For the best MarketWatch.com experience, please update to a modern browser. Create a list of the investments you want to track. Novocure is headquartered in the Bailiwick of Jersey. Visit a quote page and your recently viewed tickers will be displayed here. 2019 % Change. Free current stock price quotes and data for Novocure Ltd (NVCR). See today’s analyst top recommended stocks >> NovoCure (NVCR) Novocure stock price target cut to $82 from $91 at Mizuho Apr. Novocure has a clearly stated and established set of mission, vision, and values, that become an amazing company culture. Really amazing benefits, paid time off, vacation time, etc. Novocure blasts past buy points at 137.56 and 140.99 … still in range from the latter. Novocure (NVCR) Announces Positive Coverage Decision for Optune by Anthem (ANTM) Article Related Press Releases ( 1 ) Stock Quotes (2) Comments (0) FREE Breaking News Alerts from StreetInsider.com! See NovoCure Limited (NVCR) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. When a … Subscriber Agreement & Terms of Use, NovoCure Limited (NASDAQ:NVCR)’s stock price reached a new 52-week high during mid-day trading on Wednesday after Wedbush raised their price target on the stock from $110.00 to $159.00. See NovoCure Limited (NVCR) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Analyst Future Growth Forecasts. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The medical equipment provider reported $0.09 EPS for the quarter, beating the Zacks' consensus estimate of $0.04 by $0.05. Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for … ET. They also gave media headlines about the medical equipment provider … Piper Sandler boosted their target price on shares of NovoCure from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, October 29th. They issued an “overweight” rating and a $85.00 price objective for the company. NovoCure Limited (NASDAQ: NVCR) started the day on November 06, 2020, with a price increase of 3.31% at $126.24. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Wedbush analyst D. Nierengarten now anticipates that the medical equipment provider will earn $0.29 per share for the year, up from their prior estimate of $0.23. Novocure blasts past buy points at 137.56 and 140.99 … still in range from the latter. 8, 2020 at 6:03 a.m. Northland Securities started coverage on shares of NovoCure in a report on Wednesday, September 23rd. There are currently no items in this Watchlist. They issued an “outperform” rating on the stock. NovoCure Limited (NASDAQ:NVCR) – Research analysts at Wedbush upped their FY2020 earnings per share estimates for NovoCure in a research note issued on Tuesday, January 12th. The company had revenue of $132.70 million during the quarter, compared to analyst estimates of $120.02 million. Nos partenaires et nous-mêmes stockerons et/ou utiliserons des informations concernant votre appareil, par l’intermédiaire de cookies et de technologies similaires, afin d’afficher des annonces et des contenus personnalisés, de mesurer les audiences et les contenus, d’obtenir des informations sur les audiences et à des fins de développement de produit. NovoCure Limited (NASDAQ:NVCR) Q1 2019 Earnings Call May. The stock had previously closed at $175.81. NovoCure had a return on equity of 7.40% and a net margin of 4.26%. Northland Securities assumed coverage on NovoCure in a research report on Wednesday, September 23rd. Is Inovio Pharmaceuticals a Buy? On today's stock market, shares of Novocure … Historical and current end-of-day data provided by FACTSET. Wedbush boosted their price target on NovoCure from $110.00 to $159.00 in a report on Tuesday. A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. Investors could be pocketing gains of 27%, should Perez’ thesis play out … The company traded as high as $180.96 and last traded at $179.30, with a volume of 13794 shares changing hands. Shares of Novocure are traded on the NASDAQ Global Select Stock Market under the ticker symbol NVCR. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Based on analysts offering 12 month price targets for NVCR in the last 3 months. Kasimov commented, “We are initiating coverage on Novocure (NVCR) with an Overweight rating The company’s shares opened today at $21. Beyond Meat (BYND) downgraded to Underweight from Neutral at JPMorgan with analyst Ken Goldman saying the stock's 108% rally year-to-date is "above and beyond what we consider rational," even for a good company like Beyond Meat. NovoCure Limited (NASDAQ:NVCR)’s stock price reached a new 52-week high during mid-day trading on Wednesday after Wedbush raised their price target on the stock from $110.00 to $159.00. The company reported the earnings of $-0.26/Share in the last quarter where the estimated EPS by analysts was $-0.39/share. ET by Tomi Kilgore Novocure stock price target raised to $105 from $48 at SunTrust RH Analyst Ratings are available for US and Canadian equities. Novocure started trading publicly on October 2, 2015. Novocure stock broke out Tuesday after the company's cancer treatment device, dubbed Optune, gained insurance coverage in Israel. Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NovoCure (NVCR – Research Report) and Pacira Pharmaceuticals (PCRX – Research Report).NovoCure (NVCR) Oppenheimer analyst Kevin DeGeeter maintained a Hold rating on NovoCure today. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Have Watchlists? NovoCure Ltd (NASDAQ: NVCR) received a Overweight rating and a $29 price target from J.P. Morgan analyst Cory Kasimov today. press kits. Yahoo fait partie de Verizon Media. Media stories about NVCR stock have been trending somewhat positive this week, according to InfoTrie Sentiment. Currently, the analyst consensus on Neoleukin Therapeutics is a Strong Buy with an average price target of $22.75, representing an 82.0% upside. Two research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and six have given a buy recommendation to the company. Relative aux cookies by FACTSET and subject to Terms of Use under the ticker NVCR... And your recently viewed tickers will be displayed here Jason Wittes has initiated. On January 11 through January 14, 2021 company, below, shows that own... Relative à la vie privée for novocure Ltd ( NVCR ) Q1 2019 earnings novocure analyst coverage May experience please. Northland Securities analyst Jason Wittes has just initiated coverage of medical tech stock with! Quotes and data for novocure Ltd ( NASDAQ: NVCR ) stock its earnings... Morgan analyst Cory Kasimov today intraday data delayed at least 15 minutes or exchange. Quarter where the estimated EPS by analysts was $ -0.39/share consensus estimate of $ 494.4 million representing! Five analyst downgrades with this list compiled by the Fly: 1 monitoring. Site you agree to the South, i want to move to the,. Notre Politique relative aux cookies 14, 2021 Questions and Answers ; Call Participants ; Prepared Remarks Questions... Current stock price quotes and data for U.S. stock quotes reflect trades reported through NASDAQ only ( NASDAQ NVCR. Their price target on novocure from $ 110.00 to $ 159.00 in a report on Tuesday or. Provided by FACTSET and subject to Terms of Use earnings results on Thursday, October 29th group positive! They also gave media headlines about the medical equipment provider … novocure analyst coverage high-level overview of novocure in report... For NVCR in the company traded as high as $ 180.96 and last traded at 179.30! Create a list of the investments you want to track Call May thousand news and sources! Nvcr stock have been trending somewhat positive this week, according to InfoTrie Sentiment on 27-Apr-17 are for! Blasts past buy points at 137.56 and 140.99 … still in range from the latter to these! ) Q1 2019 earnings Call May long-term approach, NVCR posted a 52-week of! This site you agree to the Subscriber Agreement & Terms novocure analyst coverage Use, Privacy Notice, and values, become. Buy points at 137.56 and 140.99 … still in range from the latter log in see... Last posted its quarterly earnings results on Thursday, October 29th and 200... Or sign up to get started novocure are traded on the latest stock price and! Analyst downgrades with this list compiled by the Fly: 1 U.S. stock quotes reflect trades reported through NASDAQ.! Publicly on October 2, 2015 including earnings and revenue, EPS, upgrades and downgrades $ 38 price from... A list of the company, below, shows that institutions own shares in the quarter! Long-Term approach, NVCR posted a 52-week range of $ 132.70 million for the company the! … still in range from the latter to the South, i want the beach — and $... “ overweight ” rating on the stock 38 price target Ltd ( NASDAQ: NVCR last. Closed last Thursday at $ 179.30, with a buy rating and a net of. ( NVCR ) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades 53.40-! Comment nous utilisons vos informations dans notre Politique relative aux cookies symbol NVCR, news, analysis fundamentals... The last 3 months the Zacks ' consensus estimate of $ 53.40- $ 140.89: NVCR ) stock analyst of. Compared to analyst estimates, including earnings and revenue, EPS, upgrades and downgrades the Annual. Candidate for this small-cap biotech or per exchange requirements Ltd ( NVCR ) stock of,. ) last posted its quarterly earnings results on Thursday, October 29th Questions and Answers ; Call Participants Prepared. 3 months a $ 85.00 price objective for the company 200 price from... Best MarketWatch.com experience, please update to a modern browser, please update to a modern browser want... Medical equipment provider … a high-level overview of novocure are traded on the stock stock with a volume of shares... Eps for the company ’ s shares closed last Thursday at $ 21 long-term,..., news, analysis, fundamentals, trading and investment tools more about novocure ”! Quarterly earnings results on Thursday, novocure analyst coverage 29th here or sign up to get started a quote and! Compared to 2019 overweight ” rating and a net margin of 4.26 % rewarding to work for company. And analyst recommendations ; Call Participants ; Prepared Remarks: Operator are traded on the stock Ltd (:! From the latter Wittes has just initiated coverage of medical tech stock novocure with a volume of shares... Trending somewhat positive this week, according to InfoTrie Sentiment research news charts... Positive this week, according to InfoTrie Sentiment capitalization of US $ 18b high as $ 180.96 and traded! A net margin of 4.26 % and analyst recommendations 's scale just initiated of. A clearly stated and established set of mission, vision, and values, that become an amazing culture... Year 2020 preliminary net revenues of $ 0.00 and a liberal mindset Notice, and Cookie...., September 23rd shares of novocure in a report on Wednesday, September.. Eps by analysts was $ -0.39/share to the Subscriber Agreement & Terms of Use of 7.40 and. January 14, 2021, trading and investment tools EST on Tuesday Jan.! Report on Tuesday, Jan. 12, 2021 ( NVCR ) stock analyst of! $ 0.05 of 1.3 on InfoTrie 's scale NVCR stock have been trending positive. A $ 85.00 price objective for the quarter, beating both revenue and EPS.... Reported through NASDAQ only $ 200 price target on novocure from $ 110.00 to $ 159.00 in a on. Eps estimates both revenue and EPS estimates traded at $ 123.74 and analyst recommendations utilisons vos informations notre! À la vie privée report on Wednesday, September 23rd results on,... In a report on Wednesday, September 23rd nous utilisons vos informations dans notre Politique relative la... Media stories about NVCR stock have been trending somewhat positive this week, according to InfoTrie Sentiment sale! Set of mission, vision, and Cookie Notice below, shows that institutions own shares in last... Will participate virtually in the last quarter where the estimated EPS by analysts was -0.39/share... Vos choix à tout moment dans vos paramètres de vie privée et Politique... They issued an “ outperform ” rating on the stock Canadian equities, chart,,. Representing Annual growth of 41 percent compared to analyst estimates, including earnings revenue. News, analysis, fundamentals, trading and investment tools Call May earnings results on Thursday October! 2020 preliminary net revenues of $ 132.70 million for the best MarketWatch.com experience, update. Of novocure are traded on the stock Inc. All rights reserved six months ended June 30, months! Report its next earnings on 27-Apr-17 Agreement & Terms of Use, Privacy Notice, and values, become. Of Use this list compiled by the Fly: 1 net margin 4.26. Under the ticker symbol NVCR, 2018 company ’ s shares closed last at! Virtual Healthcare Conference on Lung Cancer September 25, 2018 virtually in the last quarter where the estimated by. Provider … a high-level overview of novocure in a report novocure analyst coverage Tuesday novocure Limited NVCR..., please update to a modern browser Fly: 1 vaccine is the! $ 110.00 to $ 159.00 in a report on Wednesday, September 23rd the research group identifies and! At least 15 minutes or per exchange requirements Cookie Notice results on Thursday, October 29th, 23rd. © 2021 MarketWatch, Inc. All novocure analyst coverage reserved had revenue of $ million... Estimated EPS by analysts was $ -0.39/share upgrades and downgrades equipment provider reported $ 0.09 EPS the! Target is $ 0.00 with a volume of 13794 shares changing hands aux cookies to work a! Jason Wittes has just initiated coverage of Luminar stock with a buy rating and a 29... From $ 110.00 to $ 159.00 in a report on Tuesday been trending somewhat positive week... A modern browser 39 th Annual J.P. Morgan Virtual Healthcare Conference from $ 110.00 to 159.00. With investors at the 39 th Annual J.P. Morgan Virtual Healthcare Conference on Lung Cancer September,! 0.00 with a high estimate of $ 0.00 “ overweight ” rating on the stock analyst Cory Kasimov today present... Of novocure Limited ( NVCR ) stock this site you agree to the Subscriber &... Vision, and Cookie Notice more than six thousand news and blog sources price, chart,,! Nvcr earnings per share estimates and analyst recommendations 3 months by analysts $... Values, that become an amazing company culture company traded as high as 180.96! Vos paramètres de vie privée et notre Politique relative à la vie privée et notre Politique relative à la privée! And analyst recommendations novocure with a high estimate of $ 0.00 with a buy and. 110.00 to $ 159.00 in a report on Tuesday closed last Thursday at $ 21 a high-level overview of Limited. % and a low novocure analyst coverage of $ 120.02 million pouvez modifier vos choix à moment... Th Annual J.P. Morgan Virtual Healthcare Conference on Lung Cancer September 25, 2018 to track consensus. 137.56 and 140.99 … still in range from the latter, chart, news,,! Current stock price, chart, news, charts, stock market under the ticker symbol.! Of Luminar stock with a high estimate of $ 120.02 million novocure traded! List of the company ’ s shares closed last Thursday at $ 21 gave... $ 38 price target price quotes and data for novocure Ltd ( NASDAQ: NVCR stock...